This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements include, but are not limited to information or assumptions about expenses, capital and other expenditures, financing plans, capital structure, cash flow, liquidity, management's plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested by forward-looking statements.
Important factors that could cause such differences include, but are not limited to (i) our ability to maintain regulatory approval of VAZALORE 325 mg or VAZALORE 81 mg and obtain regulatory approval for any future product candidates; (ii) the benefits of the use of VAZALORE; (iii) our ability to successfully commercialize our VAZALORE products, or any future product candidates; (iv) the rate and degree of market acceptance of our VAZALORE products or any future product candidates; (v) our ability to successfully build a sales force and commercial infrastructure or collaborate with a firm that has these capabilities; (vi) our ability to compete with companies currently producing NSAIDs and other products; (vii) our reliance on third parties to conduct our clinical studies; (ix) our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us; (xi) our ability to retain and recruit key personnel, including development of a sales and marketing function; and (xii) our ability to obtain and maintain intellectual property protection for our VAZALORE products or any future product candidates.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
PLx Pharma Management Team
Rita O'Connor, CPA
Mayme Lou Roettig,
President & CEO
CFO, Head of
PLx Pharma is focused on improving the performance of established therapeutic agents with its proprietary PLxGuard™ targeted drug delivery platform
We are driven to transform the standard of care for millions of patients
PLx Pharma Investment Highlights
Large Addressable Market Opportunity
Financial Position &
PLxGuard for multiple APIs may have the potential to:
Enhance delivery & extend patent life by optimizing absorption, reducing acute GI injury
Utilize the often faster and lower cost 505(b)(2) NDA regulatory path
VAZALORE, the first and only FDA-approvedliquid-filled aspirin capsule:
Delivers fast, reliable absorption and platelet inhibition
Causes fewer gastric erosions/ulcers vs immediate release aspirin as shown in clinical trial*
$10 billion retail market opportunity for VAZALORE:
Over 40 million patients at risk for vascular disease
Available in over 30,000 drug, grocery, mass retail and e-commerce sites in U.S.
Positioned for growth:
$80M in cash, sufficient to support VAZALORE into 2023
Identify screened compounds where PLxGuard is commercially viable - 2022
* Clinically shown on VAZALORE 325 mg after 7 days of treatment
This is an excerpt of the original content. To continue reading it, access the original document here.
PLx Pharma Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 12:11:05 UTC.